Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Noninvasive Tests for NASH

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests for NASH.
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: July 7, 2020

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:

  • Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2
  • Assessment of therapeutic response
  • Assessment of long-term patient outcomes

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/noninvasive-testing-now-and-in-the-future/slideset 

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics 


Provided by the American Gastroenterology Association.

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Unlocked slides from Brent Tetri, MD, and CCO: impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease

Brent A. Neuschwander-Tetri, MD Released: February 3, 2021

Expert commentary discussing the complex interplay among NASH, obesity, and diabetes from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 29, 2021 Expired: January 28, 2022

Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH: ketogenic diet, Mediterranean diet, and more for CCO

Rotonya Carr, MD Released: July 8, 2020

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.